Hugo Quintana, MD
Cardiovascular Disease · Pascagoula, MSNPI 1124043641
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), travel and lodging and other — rather than concentrated in one kind of arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 20.1%. 2025 is the largest year on record at $13,988, 3.0 times the $4,733 reported in 2019. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 818 payments — averaging $58.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$10K
- Angiodynamics, Inc.$8K
- Medtronic$6K
- Boston Scientific$5K
- Edwards Lifesciences$4K
- Abbott$2K
- plus $11K from 37 others
What the payments were for
- Speaking & faculty fees$2,4005%
- Travel & lodging$14,38830%
- Food & beverage$22,41847%
- Education$460%
- Gifts$750%
- Other$8,33317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$8,992
- Auryon Laser System 100-120 Vac$8,474
- COREVALVE EVOLUT R$1,475
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,454
- Carto 3 System$1,421
- JETSTREAM SC$1,036
- IN.PACT Admiral$953
- Watchman$861
- AngioJet Ultra 5000A$506
- Omnilink Elite vascular stent system$463
- WATCHMAN Access System$373
- AVVIGO Guidance System$352
- PASCAL$306
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$276
- CoreValve Evolut$238
- HawkOne$229
- Mitra Clip system$177
- ELUVIA$167
- GORE VIABAHN Endoprosthesis$150
- Supera peripheral stent system$129
How this compares
$47,660 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 866 | $814,758 |
| XareltoRivaroxaban | 311 | $307,227 |
| EntrestoSacubitril/Valsartan | 330 | $297,930 |
| Repatha SureclickEvolocumab | 65 | $49,410 |
| JardianceEmpagliflozin | 42 | $39,859 |
| FarxigaDapagliflozin Propanediol | 22 | $29,835 |
| BrilintaTicagrelor | 36 | $27,287 |
| NexletolBempedoic Acid | 17 | $16,388 |
| ClopidogrelClopidogrel Bisulfate | 1,193 | $13,988 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $13,830 |
| Valsartan | 332 | $10,391 |
| EdarbiAzilsartan Medoxomil | 23 | $9,187 |
| Propafenone Hcl ErPropafenone Hcl | 43 | $8,034 |
| Diltiazem 12hr ErDiltiazem Hcl | 29 | $7,817 |
| Propafenone Hcl | 148 | $7,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $500 | $814,758866 claims |
| Johnson & JohnsonXarelto | $638 | $307,227311 claims |
| NovartisEntresto | $528 | $297,930330 claims |
| AstraZenecaFarxiga, Brilinta | $190 | $57,12358 claims |
| Boehringer IngelheimJardiance | $400 | $39,85942 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $53 | $30,21840 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $148 | $9,18723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Pascagoula
- Mahmoud ZayedPascagoula$103K
- Ediz TasanPascagoula$42K
- Simon RizkPascagoula$16K
- William PassarelliPascagoula$15K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Lawrence LeaderHattiesburg$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.